Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Newcardio, Inc. (NWCI)

NWCI RSS Feed
Add NWCI Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 7/14/2014 11:33:13 PM - Followers: 19 - Board type: Free - Posts Today: 0

 

 

Corporate Headquarters
NewCardio, Inc.

103 Carnegie Center, Suite 300
Princeton, NJ 08540
877.332.4324

www.newcardio.com

 


THE BENCHMARK COMPANY, LLC

 

Friday 09/02/2011 06:30 AM ET - Dow Jones News
NewCardio Raised To Spec Hold From Hold By Benchmark Co

    NWCI - Daily Candlesticks  
 


 

About NewCardio

Heart Diagnostics

  • NewCardio, Inc. (OTC BB: NWCI), a cardiac diagnostic and services company, develops proprietary platform technology to dramatically improve accuracy and significantly increase the diagnostic value of the standard 12-lead electrocardiogram (ECG). NewCardio's solutions incorporate novel, state-of-the-art technology that management believes will significantly improve the diagnostic accuracy and precision of the analysis and use of signals from ECGs, without disrupting the well-established 12-lead ECG practice. The Company's technology is based on a three-dimensional approach to modeling cardiac activity using standard 12-lead ECG signals. Accordingly, New-Cardio is poised to, over time, derive value from each of the 375 million ECGs performed annually around the world. 

 

  • NewCardio is applying its proprietary technology to assess cardiac safety of new drugs in development and to improve clinical diagnosis and assessment of patients with suspected and established heart disease. Management believes this technology represents a highly significant advance and has the opportunity to be a disruptive force in markets that exceed $4.5 billion in aggregate annually

 

  • The Company recently launched its lead product, QTinno, and announced its first commercialization agreements. In March 2010, the Company achieved initial QTinno revenue, derived from the sale of SOPs and professional services to a CRO customer. In addition, NewCardio has an agreement with a top-five global pharmaceutical company that selected QTinno as its automated solution and would include this in RFPs for TQT studies going forward. The Company has signed Master Services Agreements (MSAs) with two major (top five) CROs, an additional CRO and a Dedicated Phase One unit. NewCardio has several clinical studies in progress to validate, further develop and refine its technology and products. 

 

  • Management includes thought leaders from the Intel, pharmaceuticals, medical devices (St. Jude Medical), Core Labs and the investment industry. The Company believes its broad-based management team is particularly wellsuited to advance the Company's goals and develop its technology into a set of essential diagnostic tools for the ECG segment of the cardiac diagnostics industry.

Market Opportunity

  • Key initial applications include cardiac toxicity (lethal arrhythmias) determination during new drug development,and cardiac status for acute and chronic patient management. 

 

  • The FDA requires that all new drugs be tested for potential cardiac toxicity early in development. Current methods are costly and timeconsuming.  New drugs are often tested on more than 1,000 subjects, with ECGs collected at multiple time points. Using NewCardio's 3D approach, drug sponsors and CROs can automate this process, significantly reducing the cost and accelerating the test times for drugs in development. A leading independent industry analyst estimated this market to exceed $650 million annually. 

 

  • NewCardio's products could change the way patients with chronic heart conditions will monitor their disease outside the acute care setting. The Company is developing a hand-held device that could transmit the ECG data and synthesized 12-lead data to doctors remotely. This will enable complete cardiac assessment, in contrast to current devices that enable arrhythmia monitoring only. A recent study by Frost & Sullivan estimated this market to approach $2 billion. 

 

  • The Company believes its diagnostic tools will substantially improve the accuracy and timeliness of the diagnosis and response to patients arriving at Emergency Departments with suspected acute coronary syndromes (heart attack and related conditions). NewCardio's My3KG will enable doctors to diagnose acute coronary syndromes more quickly and accurately than with traditional methods, possibly saving thousands of lives annually and reducing costs associated with unnecessary hospital admissions. With more than 70 million ECGs performed in ERs each year in the U.S. alone at an average (current) reimbursement of $30 each, this market could exceed $2 billion annually at current reimbursement rates.

 

  • Additional applications include sports medicine, screening and monitoring, significantly increasing the total market opportunity for this innovative application.


   
   

  NewCardio was selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property (IP). It is one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB's proprietary IP business intelligence platform.

PATENT PROTECTED

NewCardio Receives Notice of Allowance for Vital Patent for Cardio3KG(TM) Represents Core Patent for NewCardio's 3-D ECG platform technology

SANTA CLARA, Calif., Feb. 25 /PRNewswire-FirstCall/ -- NewCardio, Inc. (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering technology relating to NewCardio's Cardio3KG solution (formerly VisualECG or Visual3Dx). This represents the core patent for NewCardio's anticipated emergency/urgent care solution, Cardio3KG.

The Cardio3KG solution is comprised of a set of algorithms and tools that provide a comprehensive method to assess cardiac electrical activity in time and space, and to extract additional 3-dimensional information from standard 12-lead ECG signals. This may enable Cardio3KG to assess potentially fatal diseases and conditions, including acute coronary syndrome, with greater speed and accuracy than possible by standard ECG.

When issued, together with US patent 7,266,408,this will be NewCardio's second U.S. patent covering broad aspects of the Company's 3-D ECG platform technology and, particularly, specifics of Cardio3KG, the first solution targeted to take full advantage of this intellectual property.

"This action by the USPTO reinforces our continuing investment in and commitment to our novel cardiovascular diagnostic platform technology, which provides 3-D analysis of the heart's electrical activity," stated NewCardio's CEO, Branislav Vajdic, PhD. "We believe the Cardio3KG solution will substantially improve the accuracy and timeliness of response and diagnosis for patients arriving at emergency departments with heart attack symptoms and related conditions. NewCardio's Cardio3KG will enable doctors to diagnose acute coronary syndromes more quickly and accurately than with traditional methods, possibly saving thousands of lives annually and reducing costs associated with unnecessary hospital admissions. We also believe Cardio3KG, along with QTinno™ and CardioBip™, represent important steps forward in validating our 3-D ECG platform's ability to improve cardiac diagnosis, clinical outcomes, and drug safety. We are pleased that patent offices in both the US and Europe are acknowledging our proprietary claims to our core technologies."

 

App Number/
Filing Date
Brief Summary
(Products Covered)
Status
PCT/
YU2004/
00020
08/20/04
Cordless recording and telecommunication of three special ECG leads and their processing (CardioBip)
US Patent No. 7,647,093 issued 01/12/10.
EU Certificate of Patent Grant EP1659936 issued 12/26/2007. EU Patent active in DE, ES, FI, FR, IT, GB, GR, PL. Other national phases are being processed.
International Application now being examined in China, Japan, Korea and the European Union (EU).
PCT/
US2005/
001239
01/16/ 05
Visual 3-D  presentation of ECG data (my3KG, QTinno)
International Application now being examined in the China, Japan, Korea and the European Union (EU)
US 11/
036,930
1/16/04
Visual 3-D  presentation of ECG data (my3KG, QTinno)
US Patent No. 7,266,408 issued 09/04/07.
PCT/US2005/001239 International Application.
US 11/
848,221
1/16/04
Visual 3-D  presentation of ECG data (my3KG, QTinno)
Filed as divisional US Patent Application on 08/30/07. Divisional with respect to 11/036,930, filed on 1/16/04.
US PTO notice of all-claim allowance on 1/28/10. US patent 7,751,875 issued on July 6, 2010.
PCT/
US2008/
009308
07/31/07
Quantitative assessment of cardiac electrical events (QTinno)
Priority to US Provisional Application filed 08/01/07.
US Patent
Application
Device and methods for evaluating cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 07/31/08. Application # US 12/184,068. Priority to US Provisional Application filed 08/01/07.
US Patent
Application
System for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 06/12/09. Application # US 12/484,153.
US Patent
Application
Method for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 06/12/09. Application # US 12/484,156.

                     US Patent
Application
Electrocardiographic Monitoring System and Method Using Orthogonal Electrode Pattern (CardioBip)
US Patent Application filed with US PTO on 07/31/09. Application # US 12/534,064.
US Patent
Application
ECG Reconstruction For Atrial Activity Monitoring And Detection (CardioBip)
US Patent Application filed with US PTO on 11/05/09. Application # US 12/613,488.
US Patent
Application
Method for Automated EKG Analysis (my3KG)
US Patent Application filed with US PTO on 11/06/09. Application # US 12/614,352.
US Patent
Application
System for Automated EKG Analysis (my3KG)
US Patent Application filed with US PTO on 11/06/09. Application # US 12/614,354.
US Patent
Application
System and Method for Automated EKG Analysis (my3KG)
US Patent Application filed with US PTO on 11/06/09. Application # US 12/614,361.
US Provisional Patent Application
Alternative Markers For Quantitative Assessment of Cardiac Electrical Events (QTinno)
US Provisional Patent Application filed with US PTO on 12/15/09. Provisional Application # US 61/286,763.
 
US Patent Application
Atrial Fibrillation Detection based on Absence of Consistent P-Loops in Averaged Vectorcardiogram
(CardioBip)
US Patent Application filed with US PTO on 1/26/10. Application # US 12/694,236.
US Patent Application
Methods and apparatus for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 1/28/10. Application # US 12/695,128.
US Patent Application
Visual 3-D  presentation of ECG data (my3KG, QTinno)
Filed as divisional US Patent Application in 3/17/10. Divisional with respect to 11/036,930, filed on 1/16/04. Application # US 12/726,168.
PCT
Systems and Methods For Quantitative Assessment of Cardiac Electrical Events (QTinno)
Application No.:  PCT/US2010/036084
International Filing Date:  May 25, 2010
Priority of 12/484,153 and 12/484,156 filed 6/12/09
PCT
Electrocardiographic Monitoring System and Method Using Orthogonal Electrode Pattern (CardioBip)
Application No.:  PCT/US2010/44013
International Filing Date:  July 30, 2010
Priority to US Patent Application filed with US PTO on 07/31/09. Application # US 12/534,064.

                         PCT
Automated EKG Analysis (my3KG)
PCT/US2010/052373
Filed 10/12/10
Priority of: 12/614,352, 12/614,354  and 12/614,361
Title: AUTOMATED EKG ANALYSIS
PCT
ECG Reconstruction For Atrial Activity Monitoring And Detection (CardioBip)
Application No.:  PCT/US10/55174, Filed: 11/2/10
(Priority: U.S. Application No.  12/613,488; Filed: 11/5/09)
PCT
Alternative markers for quantitative assessment of cardiac electrical events (QTinno)
Application No.:  PCT/US10/60041, Filed: 12/13/10. Priority to divisional application # US 61/286,763 filed on 12/15/09.
US Patent Application
Method and apparatus for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 01/03/2011. Application # US 12/983,451. Divisional to application # US 12/184,068. Priority to US Provisional Application filed 08/01/07.
PCT
Methods and apparatus for quantitative assessment of cardiac electrical events (QTinno)
Application No.:  PCT/US2011/21739, Filed: 1/19/11. Priority of US Patent Application # US 12/695,128 filed 1/28/10.
PCT
Atrial Fibrillation Detection based on Absence of Consistent P-Loops in Averaged Vectorcardiogram
(CardioBip)
Application No.:  PCT/US2011/22455, Filed: 1/25/11. Priority of US Patent Application filed with US PTO on 1/26/10. Application # US 12/694,236.
    

 



 

Newcardio Inc, has been invited to present the results of a recent QTinno ® performance study at an upcoming conference entitled "Cardiovascular Safety in Drug Development: State-of-the-Art Assessments," sponsored by the U.S. Food and Drug Administration (FDA), the Cardiac Safety Research Consortium (CSRC) and the Heart Rhythm Society (HRS). The conference will be held in Washington, DC, on April 14-15, 2011.

Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We were delighted with the significant improvement in measurement variability and study power that we observed in this investigation. We look forward to sharing this exciting data at this important conference, which is attended by cardiovascular safety experts from regulatory bodies, pharmaceutical companies, clinical research organizations and academia. The improvement conferred by our new automated ECG selection algorithm offers sponsors the opportunity to reduce the number of subjects in a study without sacrificing study power, which may result in substantial cost savings. The new algorithm is a powerful extension of our platform technology, and further demonstrates NewCardio's ability to add value to every ECG."

Vincent Renz, CEO of NewCardio, commented, "These study results represent yet another important and substantial technological innovation for QTinno that further differentiates QTinno from competition and solidifies QTinno's position as the industry's leading automated solution for drug safety studies. This is further evidence that NewCardio will continue to enhance QTinno in order to eliminate the manual, labor intensive procedures employed in the current cardiac safety methodologies, which typically affect the drug sponsors through longer timelines, higher costs and from our findings, lower quality. We believe that our latest innovation, intelligent ECG extraction, will provide additional gains that will allow the pharmaceutical industry to complete higher quality cardiac safety analysis faster, more reliably, and at significantly lower cost."

www.b2i.us/profiles/investor/ResLibraryView.asp




 

            NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics with Acute Myocardial Infarction.

The presentation will be made at the 71st Annual ADA Scientific Sessions to be held in San Diego, CA, June 24-28, 2011. In addition, the ADA has selected this presentation to be showcased in the Guided Audio Poster Tour, which features expert moderators that share their perspectives with attendees, highlighting novel and important developments in the field.

Dr. Ihor Gussak, MD, PhD, NewCardio's Chief Medical Officer, commented, "We are delighted to present our study results at this important gathering of diabetes experts, and particularly pleased that the ADA program committee chose to feature our presentation in a moderated poster session. Accurate and timely AMI diagnosis is a matter of great concern for diabetologists, and we believe our results show that my3KG can play a major role in solving it. The moderated poster session provides the opportunity to present our results directly to leading diabetes experts, and have one-on-one interactions that will allow us to discuss and explain the importance of our results in detail."

www.b2i.us/profiles/investor/ResLibraryView.asp


Newcardio Inc. to sponsor the CBI and Applied Clinical Trials 6th Annual Cardiovascular Risk Assessment Summit

January 30, 2012 - January 31, 2012

Arlington, Virginia

http://www.cbinet.com/conference/pc12102

 

Adverse cardiovascular events may pose a considerable threat during preclinical and clinical drug development, as well as in the post-marketing phase.  As a result, the need for extensive cardiovascular risk assessment is increasingly recognized as critically important for successful drug development. CBI and Applied Clinical Trials 6th Annual Cardiovascular Risk Assessment Summit provides us with the opportunity to review the most effective strategies for understanding and assessing cardiovascular risk.

 

Topics for discussion include

 

Guiding translational research into the clinic. Identifying acceptable ranges of blood pressure and heart rate  change. Assessing automated algorithms in ECG analytics. Minimizing post-marketing cardiovascular risk occurrence.


 



NEWCARDIO, INC ON FOX BUSINESS NEWS CHANNEL

www.youtube.com/watch

 


 


Breakthrough Technology

The standard 12-lead electrocardiogram (ECG or sometimes called EKG) is a diagnostic recording of cardiac electrical activity over time. The 12-lead ECG is cardiology's most frequently used screening and diagnostic tool. Over 200 million ECGs are obtained in the developed world each year, making it the most commonly performed cardiovascular diagnostic test. The ECG has a central role in screening and diagnosis of acute coronary syndromes (heart attack) and many other common forms of heart disease, and often provides the primary basis for critical therapeutic decisions.

Unknown by many, the standard ECG contains latent information about cardiac electrical activity that in total represents the three dimensional (3D) operation of the heart. However, today's standard 12-lead ECG merely represents that data as a series of 2-dimensional time and voltage readings, which must be synthesized into a 3D model of the heart operation by a clinician. It is very difficult, and in the case of some critical parameters impossible, for humans to perform this 3D synthesis in their mind.

NewCardio has developed a new patented and patent pending technology which can process this standard ECG data, and utilize and present it an easy to read format with additional 3D clinically significant diagnostic information. Importantly, no change in clinician practice of how ECG data is collected. Simply said - NewCardio does not change the standard practice for ECG collection.

The past 40 years have brought us remarkable gains in computational power. This creates an opportunity to extract substantially more diagnostically valuable information from the ECG signal. By continuing to develop appropriate mathematical algorithms and software, NewCardio believes that its proprietary 3D approaches can significantly enhance the ECG's diagnostic utility, reduce its complexity, and improve its ease of use for the medical professional. Results of first medical trials of NewCardio's technology at Harvard University Medical School and elsewhere indicate initial results to be very encouraging.



INVESTMENT HIGHLIGHTS

  • The Company's technology uses the widely accepted, standard 12-lead ECG input and displays the signals in a three-dimensional output, providing significantly increased sensitivity accuracy and precision and the capability to automate what has historically used more costly and labor-intensive manual or semi-automated processes.

 

  • The Company is developing three unique solutions using its core platform technology, addressing three distinct and rapidly growing segments of the industry and creating planned revenue diversity.

 

  • NewCardio's first solution, QTinno™, offers the first realistic opportunity for fully automated testing in Thorough QT (TQT) and cardiac safety clinical trials. The FDA requires that all new drugs be tested (TQT) for potential cardiac toxicity early in clinical development. Current testing methods are costly and time-consuming. Management believes QTinno will significantly increase accuracy and productivity of the cardiac toxicity assessment.

 

  • The Company's initial studies have confirmed that QTinno delivers virtually identical accuracy to the existing semi-automated "gold standard", but at far lower cost and with fully automated tests completed in hours, as compared to weeks of labor-intensive manual review by cardiologists when semi-automated approaches are used.

 

  • The Company has assembled a team of talented and experienced entrepreneurs and business managers, including leaders from various industries like technology, pharma, academics, and a wide range of other scientists and professionals. The Company's new chairman is the most-prolific inventor of electrical medical devices in the world; virtually every ICD (Implantable Defibrillator) manufacturer licenses patents covering technology invented by the chairman.
                                                                                                                           

 


 
   

 Corporate Fact Sheet

www.b2i.cc/b2iContent/1645/NWCI_Corporate_Profile_11122008_113544_AM.pdf

 


 

Leadership and Advisors

The Company has assembled a team of talented and experienced entrepreneurs and business managers, including leaders from various industries like technology, pharma, academics, and a wide range of other scientists and professionals.

 

Management Team

NewCardio has assembled an experienced and skilled management team which has proven their ability to create new products and build new enterprises.

Jess Jones, M.D. - Chief Executive Officer

Dr. Jones has been a member of the Company's Board of Directors since December 2008 . From 2006 to December 2010 Dr. Jones worked with Vision Capital Advisors, LLC in New York City as the Director of Healthcare Investing, analyzing investment opportunities in the biotechnology, pharmaceutical, medical technology, and medical services fields, and assisted companies in implementing their business plans. From 2001 to 2007, Dr. Jones attended Columbia College of Physicians & Surgeons in New York City , where he received his medical degree in May 2007 . Additionally, Dr. Jones earned a BA degree from the University of Utah in 2001 and an MBA from Columbia Business School in May 2007.

Greg Sadowski - Chief Operating Officer

Mr. Sadowski has served as Senior Vice President, Client Services for NewCardio since October 2008 . In that position, he has been responsible for preparing, delivering and supporting the NewCardio cardiovascular diagnostic technology solutions, including the Professional Services, Information Technology, Customer Care and Quality Assurance groups. From October 1997 to October 2008 , Mr. Sadowski worked with eResearchTechnology (eRT), where he served on the Executive Management Team as Senior VP of eRT's Electronic Patient Reported Outcomes (ePRO) business.


 


Board of Directors

Michael E. Hanson

Mr. Hanson is a founding partner of Barnard Life Sciences, a healthcare consulting company founded in 2001. From 2004 to 2009, Mr. Hanson was a member of the board of directors, compensation and audit committees, of Indevus Pharmaceuticals. From 2002 to 2006, Mr. Hanson was a member of the board of directors, compensation and audit committees, of GlycoGenesis, an oncology-focused company. From 1998 to 2001, he was a member of the board of directors, compensation and audit committees, of MGI Pharma, Inc., which was later purchased by Eisai Pharmaceuticals. Mr. Hanson also serves on the board of directors of Z-92 Pharma and Eleos, Inc., and is also a member of Pearl Street Ventures, a venture capital firm that specializes in healthcare companies and Cardinal Equity Partners, a private equity firm. Previously, Mr. Hanson spent 25 years in positions of increasing responsibility at Eli Lilly and Company. He served as President and General Manager of Eli Lilly Japan KK from 1989 to 1992. He subsequently served as Vice President of Lilly Research Laboratories with responsibilities for the Medical Department. He culminated his Lilly career as President of the Internal Medicine Business Unit which included all cardiovascular and oncology products and became a member of the Eli Lilly and Co. Operations Committee (the senior management group of the company at that time). Mr. Hanson received a B.S. in Pharmacy from North Dakota State University and an M.S. in Hospital Pharmacy Administration from the University of Minnesota, and attended the Advanced Management Program at Harvard Business School.

Jess Jones, MD

Director since December 1, 2008. From 2006 to present Dr. Jones has worked with Vision Capital Advisors, LLC as the Director of Healthcare Investing, analyzing investment opportunities in the biotech, pharmaceutical, medical technology, and medical services fields, and assisted companies in the implementation of their business plans. From 2001 to 2007, Dr. Jones attended Columbia College of Physicians & Surgeons, where he received his medical degree in May 2007. In 2005, while attending Columbia Medical School, Dr. Jones was awarded an American Heart Association-Medical Student Research Fellowship to study post-stroke inflammatory mediators in the Department of Neurosurgery. Additionally, Dr. Jones earned a BA degree from the University of Utah and an MBA from Columbia Business School.


 



Executive Consultants

NewCardio's Executive consultants are intimately involved with day to day activities and are spending significant portion of their time working with the Company.


Vincent Renz

Vinnie has more than 26 years of experience in the information technology industry, specifically in the development and commercialization of technology products and services. He previous worked at ClinPhone, the world's leading Clinical Technology Organization which was acquired by PAREXEL International Corporation, a leading global biopharmaceutical services organization. At ClinPhone, Mr. Renz served as Chief Operating Officer. Previously, he worked for eResearchTechnology, Inc. as the Executive Vice President and Chief Technology Officer and played a key role in building eResearchTechnology's clinical technology business. Mr. Renz was also instrumental in developing the global business development and client services infrastructure to support the company's rapid growth and profitability. Mr. Renz earned an M.B.A. in Management Information Systems from Indiana University and a B.B.A. in Finance from the University of Notre Dame.

Samuel George, MD, FACC, JD - Senior Medical Consultant

Sam was formerly Director of Medical Affairs at CV Therapeutics, a cardiology faculty member and Director of the Cardiac Study Program at Duke University Medical Center, and an Established Investigator of the American Heart Association. He was also a biomedical patent attorney with Latham & Watkins LLP and is registered to practice before the U.S. Patent and Trademark Office. He holds M.D. from Washington University (St. Louis) and JD from Duke University.



 

Scientific Advisors

In addition to its management team and Board, NewCardio has assembled a world class Scientific Advisory Board of recognized experts in the area of cardiology and the sub-specialty of electrophysiology.
 

Mark Josephson, MD, SAB Chairman

Chief of Cardiology, Cardiovascular Institute, Beth Israel Deaconess Medical Center, Harvard Medical School. Professor of Medicine at Harvard Medical School. Previously Director of the Harvard Thorndike Electrophysiology Institute. He is an internationally renowned international expert in cardiac electrophysiology. Dr. Josephson is a world expert on the pathophysiology of ventricular tachycardia and has authored the definitive text of cardiac electrophysiology. In 2001, Dr. Josephson was awarded the NASPE Pioneer Award and the NASPE Fellowship Training Award.


Peter R. Kowey, MD., Advisor

Dr. Kowey is an industry leading cardiologist and a Fellow of several professional organizations and his principal area of interest is cardiac rhythm disturbances. He is currently President of the Heart Center of the Lankenau Hospital Main Line Health System and also Professor of Medicine and Clinical Pharmacology at Jefferson Medical College. He has been the recipient of over 150 grants and has authored or co-authored more than 400 papers and scientific reports. Dr. Kowey is a Fellow of several professional organizations including the Clinical Council of the American Heart Association, the American College of Cardiology, the American College of Physicians, the College of Physicians of Philadelphia, the American College of Chest Physicians, and the American College of Clinical Pharmacology. He spent nine years as a member of the Cardiorenal Drug Advisory Committee, four years on the Cardiovascular Devices Committee of the U.S. Food and Drug Administration, and is on the Expert Advisory Panel of the U.S. Pharmacopeial convention. In addition, he shttp://investorshub.advfn.com/boards/edit_ibox.aspx?board_id=13573erves as an ad-hoc consultant to 94 organizations, including many of the largest pharmaceutical companies in the world, such as Pfizer, Merck, GlaxoSmithKline, Amgen, Eli Lilly and Company, and Bristol-Myers Squibb. He has also chaired several data and safety monitoring boards for clinical trials. He is the co-editor of three textbooks regarding cardiac arrhythmia and serves as a referee for manuscript review for 25 journals, as well as sitting on the editorial boards of the Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology.

Craig M. Pratt, M.D., Advisor

Currently Professor of Medicine at Weill Cornell Medical College, Director of Research for the Methodist DeBakey Heart Center and Director of the Coronary Intensive Care Unit at The Methodist Hospital in Houston, Texas. He has served as a member of the Cardiovascular and Renal Drugs Advisory Board of the Food and Drug Administration (FDA) for 11 years, including Chairman of the Cardio-Renal Advisory Board from 1987-1993; continues to serve as a consultant to the FDA's Center for Drug Evaluation and Research. Dr. Pratt has also been the principal investigator for numerous trials of drug and device investigations for the treatment of arrhythmias, heart failure, ischemia and other cardiovascular disorders.

Dorin Panescu, Ph.D.

Dr. Panescu joined NewCardio from St. Jude Medical, Inc. (NYSE: STJ) where he most recently served as Director, Technology Development, for the Company's Cardiac Rhythm Management Division. In this role, he managed broad functional teams tasked with the development of heart failure trending and wireless remote monitoring features for implantable cardiac defibrillators and pacemakers. Before St. Jude Medical, Inc., Dr. Panescu served as Vice President of Research and Development, Operations and Intellectual Property for Refractec, Inc., where he directed R&D and Operations for the development of keratoplasty RF ablation equipment and set the company's IP strategy. Refractec, Inc. was the first company to get PMA approval from the FDA for the surgical treatment of presbyopia. Previously, he served as Sr. Director of Systems Development for Boston Scientific Corporation (NYSE: BSX), directing new product development for the Electrophysiology Division. Boston Scientific, Electrophysiology, is the world market leader in RF cardiac ablation systems. Dr. Panescu is credited with 130 issued U.S. patents and 70 published or pending U.S. patent applications covering a wide spectrum of technologies for medical devices, specifically related to devices and methods for medical imaging, diagnosis and therapies, as well as cardiac mapping and ablation. Dorin holds Ph.D. and M.S. degrees in Electrical and Computer Engineering from the University of Wisconsin at Madison.


 


 

Technology Advisors

The role of the Technology advisory Committee (TAC) is to participate in setting technology development directions and provide expert opinion and help with the current technical issue.
 

Gari Clifford, Ph.D.

Currently is a Principal Research Scientist at the Harvard-MIT Division of Health Sciences, where he is the engineering manager of a National Institute of Health (NIH)-funded research program "Integrating Data, Models, and Reasoning in Critical Care," and a major contributor to the well-known Physionet Research Resource. He has worked in industry on the design and production of several FDA-approved medical devices. Dr. Clifford has taught at Oxford, MIT, and Harvard, and is currently an instructor of Biomedical Engineering at MIT. He is on the editorial boards of Biomedical Engineering Online and the Journal of Biological Systems and has authored the definitive textbook "Advanced Methods and Tools for ECG Data Analysis," which is used by advanced students throughout the world in medical and engineering colleges and universities.

Branislav Vajdic, Ph.D.

Branislav is a founder of NewCardio and provides the strategic direction for the firm as its CEO. He is a proven creator of new technologies and has commercialized them into industry leading products. A 23 year veteran of Intel where he held various senior management positions including directing the Pentium & Flash memory development teams. He led a small team that designed Intel's first flash memory product and he holds several early Flash memory design patents. Branislav received a Ph.D. in electrical engineering from the University of Minnesota.


Professional Advisors


Morrison & Foerster LLP

Worldwide IP Attorney


Wilson Sonsini Goodrich & Rosati LLC

Corporate Attorney


Russell Bedford Stefanou Mirchandani LLP

Auditors

 

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
  The following table sets forth the number of shares of common stock beneficially owned as of March 21, 2011 (the "Beneficial Owner Date") by (i) those persons or groups known to us to beneficially own more than 5% of our common stock; (ii) each director; (iii) each executive officer; and (iv) all directors and executive officers as a group. The information is determined in accordance with Rule 13d-3 promulgated under the Exchange Act based upon information furnished by persons listed or contained in filings made by them with the SEC or by information provided by such persons directly to us. Except as indicated below, each of the stockholders listed below possesses sole voting and investment power with respect to their shares and the address of each person is c/o NewCardio, Inc., 2350 Mission College Boulevard, Suite 1175, Santa Clara, California, 95054.
 

Name of Beneficial Owner
 
Common Stock Beneficially Owned
(1)
   
Percentage of Common Stock
(2)
 
Branislav Vajdic, Ph.D. (3)
    9,208,910       27.88  
Vincent W. Renz, Jr. (4)
    1,237,137       3.89  
Richard Brounstein (5)
    690,000       2.19  
Mark W. Kroll, Ph.D., FACC, FHRS (6)
    419,896       1.34  
Robert N. Blair, M.Inst.P. (7)
    830,843       2.67  
James A. Heisch (8)
    228,790       *  
Jess Jones, M.D.
    0       *  
Patrick Maguire, M.D., Ph.D. (9)
    177,956       *  
Michael Hanson (10)
    145,877       *  
Ihor Gussak (11)
    786,705       2.49  
Dorin Panescu (12)
    755,777       2.39  
Greg Sadowski (13)
    429,208       1.38  
                 
All officers and directors as a group (12 persons)
    14,911,099       39.48  


 

Please keep this board about NWCI only! 

 

 

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NWCI
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#307   H8ster, ROCKHard 07/14/14 11:33:12 PM
#306   Investors tried. But Vision Capital, the hedge H8ster 07/12/14 05:05:39 PM
#305   any idea if there's an active legal case ROCKHard 07/10/14 07:23:48 PM
#304   Any news of anything? I don't know how inveterate 02/07/14 05:53:35 PM
#303   Wow, the company still has a pps. H8ster 01/17/14 12:49:35 AM
#302   Company Assets to be auctioned off. H8ster 03/24/13 07:26:43 PM
#301   H8ster 03/14/13 09:17:09 PM
#300   Thanks. I'll look into it. H8ster 03/14/13 09:13:19 PM
#299   Al Crespo on the Yahoo message board received inveterate 03/14/13 08:48:23 PM
#298   I don't have any updates. What gives H8ster 03/14/13 08:15:13 PM
#297   H8ster, Do you have any up to date information inveterate 03/14/13 07:33:25 PM
#296   Do you know what their combined debt totals? inveterate 03/05/13 03:31:50 PM
#295   Newcardio's management team are shareholders. They own H8ster 03/05/13 03:23:47 PM
#294   Thanks for the reply, H8ster. I was inveterate 03/05/13 03:15:00 PM
#293   Every company and patent is different. But H8ster 03/05/13 03:01:35 PM
#292   H8ster, does this seem about an expected acceptance/rejection inveterate 03/04/13 07:51:53 AM
#291   Patent Status Update as of 02/28/2012 H8ster 02/28/13 02:24:48 PM
#290   H8ster, Thank you for keeping us updated on inveterate 01/28/13 06:05:11 PM
#289   Patent Status Update, as of 01-27-2013 H8ster 01/27/13 04:14:49 PM
#288   Yes, thank you H8ster for keeping us informed. inveterate 12/15/12 09:09:18 AM
#287   Thanks H8ster, you are always on the ball! aurliz 12/13/12 10:42:29 PM
#286   Activity Update: H8ster 12/13/12 04:21:44 PM
#285   Status Update of all Newcardio US Intellectual Property H8ster 10/26/12 02:17:39 PM
#284   I dont know how to look at it McFly1 10/18/12 09:53:29 AM
#283   What do you expect for the coming future H8ster 10/17/12 04:02:59 PM
#282   What do you expect for the coming future McFly1 10/17/12 03:10:56 PM
#281   Not at all. Some of the volume H8ster 10/17/12 03:04:46 PM
#280   so you are not worried at all with McFly1 10/17/12 02:56:30 PM
#279   I, to, am liking the selling. Haha. H8ster 10/17/12 02:52:39 PM
#278   I kinda agree with the opportunity McFly1 10/17/12 11:55:30 AM
#277   Welcome to sub-penny land NWCI. H8ster 10/10/12 02:47:49 PM
#276   not much $ traded, but volume from the McFly1 10/10/12 12:19:20 AM
#275   No trials occurring at the moment. All H8ster 09/10/12 02:53:29 PM
#274   My last contact to Mr. Jesse was weeks desertwolf01 09/10/12 04:10:57 AM
#273   Does anyone know whether there are any ongoing inveterate 07/14/12 08:18:17 AM
#272   New Patent Allowance H8ster 06/25/12 03:03:13 PM
#271   Its actually a statement from an 8K. H8ster 06/21/12 07:04:16 PM
#270   To be Clear , this is nö Company desertwolf01 06/12/12 06:54:47 PM
#269   From what i understood from various discussions with desertwolf01 06/11/12 09:31:17 AM
#268   My pov is that this is a spec H8ster 06/08/12 01:13:02 PM
#267   so still waiting there. McFly1 06/08/12 12:40:05 PM
#266   Status of all Newcardio patent applications H8ster 06/05/12 03:48:14 PM
#265   Great! Thanks H8ster as always! aurliz 04/13/12 05:27:05 PM
#264   New development. Today, The USPTO approved their H8ster 04/13/12 01:44:16 PM
#263   Thanks as always! aurliz 04/12/12 03:53:45 PM
#262   Aurliz, those aren't new financials. Those are H8ster 04/12/12 02:27:49 PM
#261   Unfortunately, today, Newcardio has been downgraded within the OTCBB H8ster 04/03/12 04:46:57 PM
#260   CBI and Applied Clinical Trials 6th Annual Cardiovascular H8ster 01/31/12 03:41:00 PM
#259   This looks like a nice and quiet stock.. PENNYBUSTER 01/11/12 10:00:49 PM
#258   Biotechnology Pharmaceutical Company Selects NewCardio's QTinno for Thorough H8ster 01/11/12 12:42:01 PM
PostSubject